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Cancer remains a leading cause of morbidity and 
mortality worldwide, requiring ongoing 
development of targeted therapeutics such as 
monoclonal antibodies. Carbohydrates on 
embryonic cells are often highly expressed in 
cancer and are therefore attractive targets for 
antibodies. Stage-specific embryonic antigen-4 
(SSEA-4) is one such glycolipid target 
expressed in many cancers, including breast and 
ovarian carcinomas. Here we define the 
structural basis for recognition of SSEA-4 by a 
novel monospecific chimeric antibody 
(ch28/11). Five X-ray structures of ch28/11 Fab 
complexes with the SSEA-4 glycan headgroup 
displayed highly similar 3D structures indicating 
a stable binding mode. By adopting a horseshoe-
shaped conformation in a deep groove, the 
glycan headgroup likely sits flat against the 
membrane to allow the antibody to interact with 
SSEA-4 on cancer cells. Sialic acid of SSEA-4 
plays a dominant role in dictating the exquisite 
specificity of the ch28/11 antibody. This is 
further supported by molecular dynamics 
simulations, which show the stability of SSEA-
4 compared to SSEA-3. These high-resolution 
views of how a glycolipid interacts with an 
antibody should advance a new class of cancer-




It has long been known that glycosylation of 
malignant cells differs significantly to that of 
healthy cells (1). Aberrant glycosylation in 
cancer (associated with several glycan epitopes) 
has been associated with tumor progression and 
metastasis, and consequently, glycans are 
potential targets for therapeutic antibodies (2-5). 
Specifically, glycosphingolipids (GSLs) are a 
promising class of glycan antigens for antibody 
targeting in cancer. Acting as structural 
components of cell membranes GSLs are 
composed of one or more monosaccharides 
attached to either a sphingoid or a ceramide 
lipid. GSLs have important roles in immune cell 
function, membrane signaling, cell adhesion, 
apoptosis and cell differentiation (6-8). 
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Furthermore, GSLs are often overexpressed in 
various types of human malignancies, including 
GD2 and GD3 in melanoma (9,10) and Globo-H 
in breast and ovarian cancers (11).   
 
Stage-specific embryonic antigens (SSEAs) are 
a family of glycoconjugate antigens, consisting 
of SSEA-1 (also known as CD15 or Lewis X), 
and two related GSLs SSEA-3 (also known as 
Gb5Cer) and SSEA-4 (also known as sialyl-
Gb5Cer) (12). Both SSEA-3 and SSEA-4 are 
known cell surface markers of human 
embryonic and pluripotent stem cells. While 
their biological function is relatively unclear, 
they are known to be overexpressed in many 
cancers, including breast and ovarian cancers 
and may be very relevant to cancer stem cells 
(11,13-17). SSEA-3 and SSEA-4 share a 
common core glycan structure (Galβ1-
3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1), with 
SSEA-4 containing a terminal sialic acid 
(Neu5Acα2-3Galβ1-3GalNAcβ1-3Galα1-
4Galβ1-4Glcβ1) and both glycan headgroups are 
linked to a ceramide lipid. SSEA-4 is 
synthesized from an SSEA-3 precursor through 
the action of β-galactoside α2,3-sialyltransferase 
2 (ST3GAL2). Overexpression of ST3GAL2 
has been implicated in poor outcomes for 
various cancers, including breast and ovarian 
cancer, which suggests a potential role of SSEA-
4 in the development or maintenance of a tumor 
environment (16,18). SSEA-4 has also been 
shown to be expressed on chemotherapy-
resistant and cancer stem cell populations of 
breast and ovarian tumors (16,17). As such, 
SSEA-4 presents an attractive target for 
antibody-based cancer therapeutics. 
 
Currently, the only commercially available 
monoclonal antibodies (mAbs) against SSEA-3 
or SSEA-4 are MC631, a rat IgM anti-SSEA-3 
mAb, and MC813-70, a mouse IgG3 anti-SSEA-
4 mAb. However, both antibodies demonstrate 
some cross-reactivity, with MC813 cross-
reacting with multiple sugars including SSEA-3 
and Forssman (19). The potential cytotoxicity of 
MC631 has not yet been reported, but MC813-
70 has been shown to induce complement-
dependent cytotoxicity of highly expressing 
SSEA-4 glioblastoma multiforme cell lines in 
vitro and suppress tumor growth in vivo (19,20). 
However, without further engineering, these 
rodent mAbs are not suitable for human 
immunotherapy due to the human anti-rodent 
immune response that limits in vivo efficacy and 
safety. 
 
In response to the over-expression of SSEA-3 
and SSEA-4 on the surface of cancer cells, a 
panel of anti-SSEA mAbs were developed. The 
lead mAb was a mouse IgG3 known as FG28/11, 
which has direct cytolytic activity against 
SSEA-4 positive cells. Following 
characterization, FG28/11 was chimerized as a 
mouse-human IgG1 mAb and renamed to 
ch28/11 (Chua et al., unpublished data). 
Ch28/11 is currently undergoing preclinical 
development against a variety of SSEA-4 
positive tumor types and its characterization will 
be reported elsewhere. 
 
In this study, we report the crystal structure of 
ch28/11 Fab bound to the SSEA-4 glycan 
headgroup. From three crystal forms, five 
independent ch28/11 Fab:SSEA-4 complexes 
were determined at resolutions between 1.5 and 
2.7 Å.  All ch28/11 Fab:SSEA-4 complexes 
displayed near-identical three-dimensional (3D) 
structures for the glycan-antibody interface. Our 
findings from crystallography and molecular 
dynamics simulations explain the basis for 
ch28/11 mAb specificity for SSEA-4 and 
identify a critical role for the terminal sialic acid, 





The FG28/11 antibody is highly specific for 
SSEA-4. ELISAs were used to reveal strong 
binding of FG28/11 to SSEA-4 and a complete 
absence of cross-reactivity with closely related 
glycans SSEA-3, Globo-H and Forssman. All of 
the glycan antigens contain a GalNAcβ1-
3Galα1-4Galβ1-4Glc core with varying terminal 
sugar residues (sialic acid in SSEA-4) (Fig. 1). 
For comparison, anti-SSEA-3 antibody MC631, 
anti-SSEA-4 antibody MC813-70 and anti-
Forssman antibody M1/87 were also tested. 
MC631 bound well to SSEA-3 and SSEA-4 with 
some binding to Globo-H, and MC813 bound 
well to SSEA-3, SSEA-4 and Forssman. As 
expected, MC1/87 only bound to Forssman and 
the negative control SLex binding antibody did 
not interact with any of the four glycans (Fig. 
1A). Therefore, FG28/11 was shown to be 
monospecific for SSEA-4, while MC631 and 
MC813 both displayed cross-reactivity to 
related glycans.  




The FG28/11 mAb was further assessed by 
glycan array, where binding was tested against 
585 mammalian glycans. FG28/11 only bound 
to SSEA-4 with no cross-reactivity with any of 
the other glycans tested, whereas MC631 bound 
to SSEA-4, SSEA-3 and Galβ1-3GalNAcβ1-
3Gal (Fig. S1). In addition, tumor cell binding 
was characterized by flow cytometry of a panel 
of cancer cell lines as well as immunostaining of 
tumors. FG28/11 showed strong binding to one 
ovarian cancer cell line (SKOV3) and weak to 
moderate binding to two other ovarian cancer 
cell lines (OVCAR5 and IGROV1) as well as 
two breast cancer cell lines (T47D and MCF7), 
but was negative for binding to colorectal cancer 
cell lines (COLO205 and HCT15) (Fig. 1B and 
Fig. S2). This was confirmed by 
immunostaining, where FG28/11 stained 28% 
(223/798) of breast and 14% (41/289) of ovarian 
tumors (Fig. 1C).  
 
Production, crystallization, and structure 
determination of ch28/11 Fab:SSEA-4 
complexes. Fab was produced by papain 
digestion of ch28/11 IgG and protein A 
purification, and the purity and uniformity 
confirmed by Coomassie-stained SDS-PAGE 
and size-distribution analysis of dynamic light 
scattering (DLS) data (Fig. 2A & B). As 
expected, the purified Fab was a disulfide-linked 
dimer of 50 kDa consisting of paired heavy (H) 
and light (L) chains of approximately 25 kDa 
sizes. By DLS, the Fab sample consisted of a 
single population with an average hydrodynamic 
diameter (DH) of 6.6 nm (compared to IgG with 
an average DH of 13.8 nm). Thus, ch28/11 Fab 
was determined to be suitable for structural 
studies.  
 
To elucidate the structural basis for recognition 
of SSEA-4 by the ch28/11 mAb, crystal 
structures of the Fab:glycan headgroup complex 
were determined. Co-crystals of ch28/11 Fab 
and SSEA-4 hexasaccharide were obtained in 
three different conditions, resulting in three 
crystal forms, with the highest resolution 
structure determined at 1.5 Å (Rwork/Rfree = 
0.172/0.197) from a tetragonal P41212 crystal 
(Fig. 2C). The monoclinic P21 crystal structure 
was refined at 1.9 Å resolution (Rwork/Rfree = 
0.176/0.230). Both the tetragonal and 
monoclinic crystals had a single ch28/11 
Fab:SSEA-4 complex in the asymmetric unit. 
The hexagonal P62 crystal structure was refined 
at 2.7 Å resolution (Rwork/Rfree = 0.169/0.246) 
with three ch28/11 Fab:SSEA-4 complexes in 
the asymmetric unit (identified as complex 1, 2 
and 3). X-ray diffraction data collection and 
crystallographic refinement statistics are 
presented in Table 1. 
 
The electron density maps allowed fitting of the 
L and H polypeptide chains for each Fab 
structure, except for one disordered loop in the 
H chain constant domain, which is distant from 
the antigen-binding site and often missing from 
Fab structures (21). The missing CH1 residues 
were 133-137 for the 2 higher-resolution 
structures, 132-137 for complex 1 and 2, and 
133-134 for complex 3 from the lowest 
resolution structure (sequential numbering). In 
all structures, there is strong electron density 
corresponding to binding site residues and five 
of the six sugar residues of SSEA-4 (slightly 
weaker electron densities were associated with 
the terminal glucose), but the entire 
hexasaccharide was fitted into electron density 
maps (Fig. 2D & Fig. S3).  
 
Groove-type recognition of the SSEA-4 
glycan by the ch28/11 mAb. The 3D structures 
for each of the five versions of ch28/11 
Fab:SSEA-4 complexes were very similar, with 
SSEA-4 positioned to fill a deep groove-shaped 
binding site (Fig. 3). The Fab has a quaternary 
structure typical of most antibodies with the 
binding site formed by six complementarity-
determining regions (CDRs), three from the L 
chain (identified as L1, L2, and L3) and three 
from the H chain (identified as H1, H2, and H3). 
The Fv portions (comprised of VL and VH; 
sequences presented in Fig. S4) were shown to 
be near-identical in 3D structure, with most of 
the minor variations occurring in loops 
surrounding the binding groove (CDRs and 
some framework region loops). The constant 
regions (comprised of CL and CH1) also showed 
some differences (Fig. 3A & Fig. 3B). A surface 
view of the 1.5 Å resolution structure illustrates 
that the center of the binding site is occupied by 
the H3 loop, with the SSEA-4 hexasaccharide 
bent around this loop in a horseshoe-like 
conformation (Fig. 3C).  
 
Antibody bound conformation of the SSEA-4 
hexasaccharide. In the ch28/11 binding site, the 
SSEA-4 hexasaccharide is surrounded by all six 
CDRs (L1-3 and H1-3) and snugly fills the entire 
binding groove (Fig. 3 & Fig. S5). This snug fit 
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corresponds to a stable glycan conformation 
where the galactose (GAL2, GLA4, and GAL5), 
N-acetyl-galactosamine (NGA3) and terminal 
sialic acid (SIA1) residues all display very little 
movement between structures (Fig. 4; see figure 
for monosaccharide codes). In contrast, the 
terminal glucose (BGC6) that would normally 
be attached to the ceramide lipid, exhibits more 
flexibility in its position (Fig. 4A & B), which 
corresponds with it being the most solvent-
exposed portion of the SSEA-4 glycan (Fig. 3). 
Further examining the conformations of the five 
SSEA-4 hexasaccharide structures in a 
Ramachandran-like plot showed clustering of 
the phi and psi angles of the various glycosidic 
linkages (Fig. 4C). The same glycosidic 
conformations were observed for SIA1-GAL2 
and GLA4-GAL5 as demonstrated by similar 
phi and psi angles. GAL2-NGA3 and NGA3-
GLA4 glycosidic linkages have similar psi but 
different phi angles indicating different 
conformations for these linkages. In line with its 
position in the binding site and flexibility, a 
distinct cluster with a larger variation of phi and 
psi angles occurred for the GAL5-BGC6 
glycosidic linkage (Fig. 4C).  
 
Molecular details of ch28/11 Fab recognition 
of the glycan headgroup of SSEA-4. In each of 
the five structures, the Fab participates in 
numerous hydrogen-bond and van der Waals 
interactions with each of the six sugar residues 
of SSEA-4 (Fig. 5 & Fig. S6). All antibody 
residues involved in binding SSEA-4 are located 
within the L and H chain CDRs, except for one 
residue (His 33L), which forms a single 
hydrogen-bond with the glycan ligand in each 
structure (see Fig. S4 for glycan contact residues 
and numbering schemes). A total of 791.5 Å2 of 
the SSEA-4 glycan headgroup is buried in the 
ch28/11 binding groove. Contributions to the 
interaction of ch28/11 mAb and glycan for the 
constituent monosaccharides are: SIA1, 202.0 
Å2; GAL2, 117.5 Å2; NGA3, 167.6 Å2; GLA4, 
141.5 Å2; GAL5, 118.7 Å2; BCG6, 44.2 Å2. 
 
Within the expansive ch28/11 binding groove, 
contacts are made with each residue of SSEA-4. 
Sialic acid (SIA1) dominates the interaction 
with the antibody by participating in more 
contacts compared to any other residue in the 
glycan chain. It is secured in place by hydrogen 
bonds between the nitrogen on the N-acetyl 
moiety and Ser-31H, the O8 hydroxyl and Gly-
33H, and from the carboxylate group to Gly-53H 
and Asp-54H. The N-acetyl-galactosamine 
(NGA3) of SSEA-4 is involved in hydrogen 
bonds from the O4 and O6 hydroxyls to Tyr-93L 
and Ala-90L, respectively. The a-galactose 
(GLA4) engages in one hydrogen bond from the 
O4 hydroxyl to Ala-90L and two hydrogen 
bonds from the O6 hydroxyl to His-33L and 
Gly-101H. The next galactose in the chain 
(GAL5) is involved in three hydrogen bonds 
from the O2 and O3 hydroxyls to Asp-49L. In 
contrast, galactose at position 2 (GAL2) and 
glucose at position 6 (BGC6) do not engage in 
direct hydrogen bonding with the ch28/11 mAb. 
SSEA-4 is further stabilized by numerous van 
der Waals interactions between binding site 
residues and each monosaccharide in the glycan 
chain (Fig. 5).  
 
The ch28/11:SSEA-4 interface (at 1.5 Å 
resolution) has a well-defined solvent structure 
with 23 ordered water molecules surrounding 
the SSEA-4 glycan. Sialic acid (SIA1) again 
dominates the interactions with 8 ordered waters 
involved in stabilising its conformation in the 
binding groove. Other monosaccharide units of 
SSEA-4 are involved in fewer water-mediated 
interactions: GAL2, 5 waters; NGA3, 4 waters; 
GLA4, 4 waters; GAL5, 3 waters; BCG6, 3 
waters.  
 
A solvent-accessible surface representation 
shows SSEA-4 snugly fitted into the binding 
groove of the Fab, folding around the centrally 
located H3 loop in a horseshoe-shaped 
conformation, with the N-acetyl-galactosamine 
hydrophobic face stacking against the Tyr-102H 
side chain to slot into its position in the deepest 
part of the binding groove (Fig. 6A & B). Thus, 
the ch28/11 binding groove is totally occupied 
by the SSEA-4 glycan headgroup and the 
ordered water molecules to present an almost 
continuous convex surface at the end of the Fab. 
The absence of protruding CDR loops would 
permit the intact ch28/11 mAb to bind closely to 
the cell membrane where the SSEA-4 
hexasaccharide is directly anchored by its 
ceramide tail. This could be relevant for the 
direct cytotoxic activity of the ch28/11 antibody.  
 
Structure of the unliganded ch28/11 Fab 
reveals conformational changes are involved 
in recognition of SSEA-4. To further examine 
the SSEA-4 binding mechanism, the crystal 
structure of the unliganded ch28/11 Fab was 
determined. X-ray diffraction data was obtained 
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from a monoclinic P21 crystal at 2.5 Å resolution 
(Rwork/Rfree = 0.164/0.239; Table 1). There were 
two Fabs in the asymmetric unit, both with clear 
electron density maps in the binding site (Fig. 
S3). Differences in 3D structure of the binding 
sites are mainly due to crystal packing, where 
the variable domains of Fab 2 are packed against 
the light chain of the constant domain of Fab 1. 
To compare free with bound structures, the Fv 
regions from the unliganded Fabs were 
superimposed on the 1.5 Å resolution ch28/11 
Fab:SSEA-4 structure. For the most part, there 
is little variation in binding site residues, with 
the exception of CDR3 of the heavy chain. In the 
free Fab structures, this loop appears to collapse 
into the binding groove, with the Tyr-102H side 
chain in particular shifting inward to fill part of 
the groove (Fig. 7 and Fig. S5). A multitude of 
small conformational differences occur in the all 
H chain CDRs around the site of interaction with 
sialic acid of SSEA-4. Overall these results 
suggest SSEA-4 recognition by the ch28/11 
mAb represents an induced fit binding 
mechanism.  
 
Structural basis for ch28/11 specificity for 
SSEA-4. Molecular dynamics (MD) simulations 
were performed to examine why the ch28/11 
mAb does not cross-react with SSEA-3, which 
compared to SSEA-4 is only missing the 
terminal sialic acid residue. Carbohydrate 
flexibility can be assessed by examining root-
mean-square fluctuation (RMSF) of 
carbohydrate residues, which is a time-averaged 
measure of atom deviation from a reference 
position. RMSF analysis of carbohydrate 
residues, averaged over 1.5 µs of MD 
simulations, show that the central galactose and 
N-acetyl-galactosamine residues (numbered 3-
5) are highly stable in the binding site for both 
SSEA-3 and SSEA-4. Additionally, in both 
glycans the terminal glucose (BCG6) was 
mobile in the binding site, although more so for 
SSEA-3. For SSEA-3, the galactose at position 
2 (GAL2) displayed high RMSF values, while 
the same residue in SSEA-4 was highly stable 
across the MD simulations (Fig. 8A & B). This 
is further evident when examining the phi (ϕ) vs. 
psi (ψ) plots of each glycosidic linkage. The 
linkage between galactose (GAL2) and N-
acetyl-galactosamine (NGA3) is more flexible 
in SSEA-3 displaying a range of conformations 
when compared to SSEA-4. It should also be 
noted that the linkage between galactose 
(GAL5) and the terminal glucose (BGC6) is also 
more flexible in SSEA-3 when compared to 
SSEA-4 (Fig. 8C & D). When overlaying the 2 
main ligand conformations of SSEA-3 taken 
from MD simulations, there is good alignment 
of the three central carbohydrate residues, and 
the largest difference in conformation occurs 
with the GAL2 and BCG6 monosaccharides 
(Fig. 8E). Therefore, it can be concluded that the 
ch28/11 binding groove is more stable in the 
presence of SSEA-4 due to the presence of the 
terminal sialic acid residue absent in SSEA-3. 
Furthermore, the sialic acid (SIA1) of SSEA-4 
was highly stable during MD simulations (Fig. 
8B) as is the SIA1-GAL2 glycosidic linkage 
(Fig. 8D), which supports its critical role in 





Traditionally cancer therapies have been broad 
acting and non-specific, such as surgery, 
chemotherapy, and radiotherapy. However, 
there has been an increasing trend towards 
targeted therapeutics with greater specificity and 
reduced off-target effects. These include several 
glycoprotein-specific antibody-based therapies, 
such as trastuzumab (Herceptin) for metastatic 
HER2-overexpressing breast cancers (22) and 
cetuximab (Erbitux) for HER1-positive 
colorectal carcinomas (23).  Dinutuximab 
(Unituxin) was the first carbohydrate-binding 
antibody approved as a treatment for GD2-
positive pediatric neuroblastomas (24). Another 
class of successful cancer therapeutic antibody, 
generically called checkpoint inhibitors, work 
by activating the immune system of patients. 
Examples include ipilimumab (Yervoy) that 
targets CTLA-4 for the treatment of advanced 
melanoma and renal carcinomas (25) and 
atezolizumab (Tecentriq) that binds PD-L1 and 
was first introduced to treat bladder and urinary 
tract cancers (26,27). Thus, most antibody-based 
therapies either target specific signaling 
pathways or cancer-specific antigens, allowing 
immune recognition of cancer cells. Despite 
their growing use, most approved therapeutic 
antibodies are only indicated for specific and 
limited types of malignancies. Although there 
are many antibody-based therapies in 
development, there is a distinct need for 
continued identification of new mAbs to 
complement existing therapies (5,28,29). 
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Antibodies targeting glycans and particularly 
glycolipid antigens have great potential for 
cancer immunotherapy but have to date 
progressed slowly mainly due to challenges with 
development, specificity and efficacy (3,4). In 
addition, for glycan antibodies to have 
meaningful prognostic value, monospecificity is 
crucial. Collectively, our structural studies with 
the newly developed ch28/11 mAb have 
provided unique and surprising insights into its 
recognition of SSEA-4, which represents a 
promising glycolipid target in a range of cancers 
(11,13-15). The SSEA-4 glycan headgroup is 
almost completely engaged by snugly fitting 
into a deep groove of ch28/11 Fab in a 
horseshoe-shaped conformation. SSEA-4 is 
securely bound by numerous hydrogen bonds, 
van der Waals interactions and a large network 
of well-defined water molecules. The high level 
of binding site occupancy enables the secure 
antigen specific binding between ch28/11 and 
SSEA-4, which is replicated across the five 
high-resolution crystal structures. In contrast, 
Kannagi et al. showed that SSEA-4 antibody 
MC813 recognizes the terminal 3 sugars 
(NeuAα2-3Galβ1-3GalNAc) whereas anti-
SSEA-3 antibody MC631 recognises the middle 
3 sugars (GalNAcβ1-3Galα1-4Gal). This could 
explain the exquisite specificity displayed by 
ch28/11 towards SSEA-4 compared to the cross-
reactivity of MC813 with SSEA-4, SSEA-3 and 
Forssman glycans (see Fig. 1) (20).  
 
In the context of an intact ch28/11 mAb binding 
to the surface SSEA-4 positive cells, binding 
must involve intimate contact with the cell 
membrane where the glycan epitope is pushed 
flat against the lipid bilayer. Interestingly, the 
terminal sialic acid of SSEA-4 dominates 
interactions with the ch28/11 mAb in the section 
of the groove formed exclusively by H chain 
CDRs. An induced fit mechanism of SSEA-4 
recognition is evident by comparisons of the 
bound and free ch28/11 Fab structures. The 
ligand-induced conformational changes in the 
binding groove and sialic acid pocket may partly 
explain the specificity of ch28/11 mAb for 
SSEA-4. More compelling is the increased 
mobility of the related SSEA-3 glycan, which 
lacks the terminal sialic acid and is not 
recognized by ch28/11. All these observations 
point towards binding and specificity for SSEA-
4 by the ch28/11 mAb requiring at least 5 
monosaccharides of the glycan headgroup and 
critically depending on the presence of the sialic 
acid residue. Also considered as a cancer-related 
glycolipid, Globo-H is an a1-2 fucose 
substituted SSEA-3 and is not recognized by 
ch28/11 (Fig. 1). The proximity of the Gal O2 to 
the H3 loop and the prominent Tyr 102H side-
chain (see Fig. 5) suggests that Globo-H does 
not cross-react with ch28/11 due steric clashes 
imposed by the terminal fucose. 
 
To date, ch28/11 is only the second glycolipid 
binding antibody for which a structure of the 
complex with the glycan has been resolved. The 
GD2 binding antibody 14G2a recognizes the 
branched glycan headgroup by end-on insertion 
and interacts with 4 of the 5 monosaccharides. 
This suggests a perpendicular binding mode of 
the 14G2a mAb for the GD2 ganglioside (30) as 
compared to the parallel binding proposed for 
the ch28/11 mAb.  
 
Crystal structures for several other glycolipid 
mAbs have been determined as free Fabs, with 
docking and molecular modeling used to predict 
the carbohydrate binding mode. Three studies 
suggest that the terminal sialic acid of GD3 and 
NeuGc-GM3 bind in pockets formed by the H 
chain only (31-33). In two of the reported Fab 
structures (R24 and chP3 mAbs), the CDR loops 
of the H chain form binding pockets large 
enough to accommodate the terminal sialic acid 
by end-on insertion (31,32). For the NeuGc-
GM3 binding antibody 14F7, the structure 
revealed an extended CDR H3 loop that divides 
the binding site into 2 subsites, with the model 
showing the ligand binding to the subsite formed 
solely by H chain (33). In another structure, 
molecular docking simulations of the anti-GD2 
antibody 3F8 showed the terminal sialic acid of 
GD2 binding between the H and L chains, with 
the second sialic acid binding primarily to the H 
chain (34). Similar to these predicted 
interactions, ch28/11 also binds sialic acid 
entirely through a subsite formed by the H chain 
CDRs, which supports the concept that the H 
chain repertoire may be predisposed towards 
sialic acid recognition. 
 
By comparison, the structure of another GD2 
binding antibody ME36.1 has a relatively 
straight groove-shaped binding site (not a 
pocket), where it is proposed that all six CDRs 
are involved in binding to the tetrasaccharide 
(Neu5Acα2-8Neu5Acα2-3Galβ1-4Glc) in an 
extended conformation (35). This type of 
groove-shaped recognition has been observed 
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for antibody binding to an extended 
pentasaccharide epitope expressed by many 
microbes (36). In contrast, ch28/11 binds the 
glycan in a horseshoe-shaped conformation in a 
groove that accommodates the hexasaccharide 
glycan headgroup of SSEA-4. 
 
Inspection of the sialic acid binding pocket of 
ch28/11 shows the carboxylate anchored by two 
hydrogen bonds to main-chain and the N-acetyl 
nitrogen and O8 positions also hydrogen bonded 
to binding site residues (Fig. 5). The remaining 
oxygen atoms of the sialic acid interact with 
ordered water molecules. Similar binding modes 
have been observed in viral and bacterial lectins 
where the carboxylate of the sialic acid is 
anchored by at least 2 hydrogen bonds. 
However, other lectins interact with the sialic 
acid carboxylate by ionic interactions with 
arginine or lysine residues (based on PDB 
structures annotated by ProCarbDB) (37).  
Furthermore, most sialic acid binding lectins 
interact with the terminal sialic acid or only a 
couple of monosaccharides of longer glycan 
ligands, compared to ch28/11 interacting with 
all 6 monosaccharides of the SSEA-4 glycan 
headgroup. Sialic acids of tumor glycans can be 
incorporated from the diet as the N-glycolyl 
form that is not normally found in humans (i.e., 
Neu5Gc) or can be O-acetylated usually at the 
O9 position (38,39). Although we have not 
experimentally tested these modifications, both 
Neu5Gc or O9-acetylation appears compatible 
with the ch28/11:SSEA-4 interaction as both 
sites are solvent exposed (see Fig. 5) and 
relatively unobstructed by binding site residues.  
 
Here we define the molecular basis for 
recognition of SSEA-4 by ch28/11, a newly 
developed mouse-human chimeric antibody. 
Our findings reveal the structural basis for the 
ch28/11 mAb selectively binding to SSEA-4. 
Understanding the molecular details of glycan 
recognition will allow for future structure-based 
design of highly effective glycan specific mAbs 




Direct binding ELISAs of glycan antigens 
coupled to BSA. Glycan-BSA conjugates were 
obtained from Elicityl, France. Glycans were 
characterised by NMR prior to conjugation and 
TLC and HPAEC-PAD after conjugation with 
10-40 glycan molecules per BSA. ELISA plates 
were coated overnight at 4°C with 100 ng/well 
glycan-BSA antigens in PBS, blocked with PBS 
10% w/v BSA and incubated with primary 
antibodies (5 μg/ml). Primary antibodies were 
FG2811 (anti-SSEA-4) (University of 
Nottingham, UK), MC631 (anti-SSEA-3) 
(eBioscience, USA), MC813 (anti-SSEA-4) 
(Abcam, UK), M1/87 (anti-Forssman) (Santa 
Cruz Biotech, USA), and anti-sialyl-Lewis X 
(Biorbyt, UK). Glycan antigen binding was 
detected using anti-mouse, anti-human or anti-
rat IgG Fc specific biotinylated antibody 
(Sigma, UK) [1/5000 dilution in PBS 1% w/v 
BSA], followed by streptavidin horseradish 
peroxidase (HRPO) conjugate (Sigma, UK) 
[1/5000 dilution in PBS 1% w/v BSA] and 
development with 3,3’,5,5’-
Tetramethylbenzidine (TMB). Absorbance was 
measured at 450nm using a Tecan infinite F50 
plate reader.  
 
Glycan array analysis. FG28/11 and MC631 
were screened for binding to 585 glycans on the 
Consortium for Functional Glycomics (CFG) 
mammalian glycan array (core H group, version 
5.1). Slides were incubated with 10µg/ml of 
antibody for 1 hour, before detection with Alexa 
Fluor488-conjugated secondary mAb. 
 
Immunohistochemistry assessment. Tumor 
tissue binding was analyzed by 
immunohistochemistry as described previously 
(40). Briefly, after antigen-retrieval, blocking of 
endogenous peroxidase activity and non-
specific binding sites, the sections were 
incubated with primary mAbs at room 
temperature for 1 hour.  Primary mAb binding 
was detected by biotinylated secondary mAb 
(Vector Labs, USA) followed by preformed 
streptavidin-biotin/HRPO (Dako Ltd, UK) and 
3, 3’-Diaminobenzidine as the substrate.  
Finally, sections were counterstained with 
hematoxylin.  Staining was analyzed via New 
Viewer software 2010. 
 
Patient cohorts. The study populations include 
cohorts of consecutive series of 350 ovarian 
cancer (41) samples (1982-1997; median follow 
up 192 months: censored November 2005: 
patients with stage II to IV disease received 
standard adjuvant chemotherapy which in later 
years was platinum based), 798 primary breast 
cancer (42) samples (1987-1998; median follow 
up, 177 months). Patients were selected for 
systemic adjuvant treatment on the basis of 
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Nottingham Prognostic Index (NPI) score and 
hormone receptor status [patients with NPI score 
≤ 3.4 received no adjuvant therapy; those with 
an NPI score higher than 3.4 received tamoxifen 
if they were estrogen receptor (ER) positive (± 
goserelin if premenopausal) or classical 
cyclophosphamide, methotrexate and 
fluorouracil if they were ER negative and if 
capable of tolerating chemotherapy]. 
 
Flow cytometry. Cells (1 x 105) were incubated 
with primary mAbs at 4oC for 1 hour followed 
by FITC-conjugated anti-mouse IgG Fc specific 
secondary mAb (Sigma, UK). Cells were 
resuspended in PBS and run on a Beckman 
Coulter FC-500 with WinMDI 2.9 for analysis.   
 
Recombinant ch28/11 IgG and Fab 
production. Recombinant ch28/11 IgG was 
expressed in Expi293 cells (Thermo Fisher 
Scientific) and purified by filtration and fast 
protein liquid chromatography (FPLC) using 
HiTrap protein G columns (GE Healthcare). A 
Pierce Fab Preparation Kit (Thermo Fisher 
Scientific) was used to produce Fab from IgG. 
Briefly, 0.5 mL of an 8 mg/mL IgG sample was 
digested with Papain-agarose for 6 hours at 
37°C. Fc and residual intact IgG was separated 
from Fab using protein A affinity 
chromatography. Coomassie stained SDS-
PAGE (precast 4-15% Bis-Tris Mini Gels and 
MES running buffer, BioRad) was used to 
examine the purity of the Fab compared to the 
Fc and intact IgG samples under non-reducing 
and reducing (β-mecaptoethanol) conditions. 
Fab was quantitated by absorbance at 280 nm 
(Nanodrop) assuming a mass extinction (E, 
derived concentrations in mg/mL) value of 1.0 
(1.37 for intact IgG). DLS was used to determine 
protein size and polydispersity using a Zetasizer 
nano ZS instrument (Malvern Instruments). 
Disposable cuvettes containing 100 µL of 
protein sample were measured (five replicates) 
at 25°C, to generate intensity reports showing 
size distribution by intensity to identity 
population peaks (by size (d.nm) and % 
intensity), and Z-average hydrodynamic 
diameters (DH, in nm) and polydispersity were 
estimated by the cumulants method.  
 
Crystallization of ch28/11 Fab in complex 
with SSEA-4 hexasaccharide. For 
crystallization, ch28/11 Fab was dialysed 
overnight into ultrapure water (Milli-Q) using 
Slide-A-Lyser MINI Dialysis devices with a 10-
kDa-cutoff. Fab samples were concentrated to 
10-20 mg/mL using Pall Corp Nanosep 
OMEGA devices with a 3 kDa cut-off 
membrane.  Co-crystallization of the SSEA-4 
glycan headgroup (SSEA-4 hexaose, 
Carbosynth) with ch28/11 Fab was achieved 
with a molar ratio of 5:1 (carbohydrate:protein). 
Initial crystals were generated by the sitting-
drop vapor diffusion method at 18°C in a 96-
well sitting drop plate (Corning) using the 
Crystal Screen High Throughput kit (Hampton 
Research). Reservoirs of 80 µL of each 
crystallization condition were used with 1 µL of 
Fab:SSEA-4 sample mixed with 1 µL of the 
same condition for the sitting drop. Improved 
crystals were obtained in 24-well hanging drop 
plates (18°C) with 1 mL reservoirs and 1µl of 
Fab:SSEA-4 mixed with 1 µL of crystallization 
condition for the hanging drop. Crystals suitable 
for X-ray diffraction were produced in the 
following crystallization conditions: 25% v/v 
polyethylene glycol (PEG) 4000, 0.1 M sodium 
acetate pH 4.6 and 0.2 M ammonium sulfate 
(P41212 crystal form); 20% PEG 8000, 0.1 M 
Sodium Cacodylate pH 6.5 and 0.1 M 
Magnesium Acetate (P21 crystal form); 20% 
PEG 4000, 10% iso-Propanol and 0.1 M Sodium 
HEPES pH 7.5 (P62 crystal form). The free 
ch28/11 Fab crystals crystallized in 20% PEG 
4000, 10% iso-Propanol and 0.1 M Sodium 
HEPES pH 7.5. For data collection, crystals 
were mounted in nylon loops (Hampton 
Research) in the drop solution and plunged into 
liquid nitrogen. Some crystals from the highest-
resolution condition were frozen in the presence 
of 10% ethylene glycol in crystallization media 
as a cryoprotectant, but a cryoprotectant was not 
needed for most crystals. 
 
Data collection and structure determination. 
Diffraction data were collected at the Australian 
Synchrotron using the MX2 beamline, by the 
ultrafine φ-slicing data-collection method using 
an EIGER X 16M detector and the qeGUI 
graphical user interface. Diffraction data were 
auto processed on the MX2 beamline using 
automated indexing with xdsme (using XDS and 
Pointless) and AIMLESS (43,44). Data 
processing and hkl file conversions were 
implemented in the XDS and the CCP4 program 
package (45,46). All modeling and 
crystallographic refinements were performed 
using Phenix, COOT and REFMAC (47-49). 
Validation of SSEA-4 was performed in the 
CCP4 program package with PRIVATEER 
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(45,50). LigPlot+ version 1.4 was used to 
generate the ligand interaction diagrams (51). 
Figures were generated using Discovery Studio 
(Dassault Systèmes BIOVIA, USA).  
 
Crystals belonged to space groups P41212 (1.5 Å 
resolution), P21 (1.9 Å resolution) and P62 (2.7 
Å resolution), with the highest resolution 
structure determined by molecular replacement 
using Protein Data Bank (PDB) code 1A7N for 
VL:VH and PDB code 3IU4 for CL:CH1. 
Crystals of the free Fab belonged to space group 
P21 (2.5 Å resolution). Several rounds of fitting 
of the atomic model to electron density and 
crystallographic refinement were conducted. 
The final atomic model of the highest-resolution 
structure was used for molecular replacement of 
the other versions. Following multiple rounds of 
crystallographic and amino acid refinement, all 
ch28/11 Fab: SSEA-4 structures were of high 
resolution with strong fit of the ligands in the 
binding site. Data collection and refinement 
statistics are reported in Table 1. 
 
MD simulations of complexes of ch28/11 Fab 
with SSEA-3 and SSEA-4. MD simulations 
were run using GROMACS 2018.2 (52,53). 
Proteins were parameterized using the 
AMBER99SB-ILDN forcefield (54). 
Carbohydrate topologies were generated using 
the Glycam06j forcefield via GLYCAM-Web 
(http://glycam.org), converted to GROMACS 
format using ACPYPE (55,56) and combined 
with the protein topology to form the complete 
protein-carbohydrate system. Initial coordinates 
for the protein-carbohydrate system for both 
SSEA-3 and SSEA-4 were based on the 1.5 Å 
resolution ch28/11 Fab:SSEA-4  structure (with 
the terminal sialic acid residue removed for 
SSEA-3). The protein-carbohydrate system was 
placed in a rhombic dodecahedral box with ≥10 
Å distance between the molecule and the edge of 
the box. The system was solvated using the 
TIP3P water model, then ionised and neutralised 
with Na+ and Cl- to a concentration of 0.15 M. 
Energy minimization was performed using the 
steepest descent algorithm (5000 steps), follow 
by equilibration at constant volume and 
temperature (NVT ensemble) for 100 ps, with 
each replicate initialized with random velocities 
sampled from a Maxwell distribution at 300 K. 
This was followed by equilibration with 
constant pressure and temperature (NPT 
ensemble) for 300 ps. Pressure coupling was 
achieved via the Parrinello-Rahman barometer 
with a time constant of 2 ps and a reference 
pressure of 1 bar. Temperature coupling was 
achieved using the modified Berendsen 
thermostat, with separate temperature coupling 
groups for ligand/protein and water/ions 
respectively. A time constant of 0.1 ps was used 
for temperature coupling, with a reference 
temperature of 300 K. Equations of motion were 
integrated using the leap-frog integrator with a 
time-step of 2 fs. Hydrogen bonds were 
constrained during all steps using the LINCS 
constraint algorithm (57). Long range 
electrostatics were calculated using the Particle 
Mesh Ewald (PME) method with cubic 
interpolation. Neighbor searching was 
performed using the Verlet cut-off scheme with 
a distance cut-off of 1.0 nm for both Coulomb 
and van der Waals interactions. Simulations 
were run for 500 ns with 3 replicates per 
complex (for a total of 1.5 μs per complex) using 
the Spartan high-performance computer system 
(University of Melbourne).   
 
Analysis of MD simulations was performed 
using a combination of GROMACS 2018.2 and 
the MDTraj Python package (v1.9.1). Root-
mean-square fluctuation (RMSF) of 
carbohydrate atoms was calculated relative to 
the protein backbone carbon atoms (i.e. protein 
backbone carbon atoms were used to remove 
rotational and translational movement across 
frames, and RMSF calculated for these 
transformed trajectories). The glycosidic phi and 
psi angles were calculated using the MDTraj 
package. All visualization was performed using 
the Matplotlib 1.5 and Seaborn 0.9.0 Python 
libraries. Figures were generated in VMD 1.9.3 
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BGC, glucose; CDR, complementarity-determining region; Fab, fragment antigen-binding; Fv, 
variable fragment; GAL, β-galactose; GLA, α-galactose; GSLs, glycosphingolipids; HPAEC-
PAD, High-Performance Anion-Exchange Chromatography Coupled with Pulsed Electrochemical 
Detection; HRPO, horseradish peroxidase; mAb, monoclonal antibody; MD, molecular 
dynamics; NGA, N-acetyl-galactosamine; NMR, nuclear magnetic resonance; PEG, polyethylene 
glycol; RMSF, root-mean-square fluctuation; SIA, sialic acid; SLex, sialyl-Lewis x; SSEA, 
stage-specific embryonic antigen; SSEA-3, stage-specific embryonic antigen-3; SSEA-4, 
stage-specific embryonic antigen-4; ST3GAL2, β-galactoside α2,3-sialyltransferase 2; TLC, 
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Figure 1. Assessment of FG28/11 specificity towards SSEA-4. A) Binding of FG28/11 mAb to (i) 
SSEA-3-BSA, (ii) SSEA-4-BSA, (iii) Globo-H-BSA and (iv) Forssman-BSA glycans was assessed by 
ELISA. MC631, MC813-70 and M1/87 were included as positive control mAbs for SSEA-3, SSEA-4 
and Forssman glycans, respectively. Anti-sialyl-Lewis x antibody and biotinylated anti-mouse IgG 
secondary antibody (no ab) were used as negative controls. Antibody activity was measured by 
absorbance at 450nm. Error bars represent mean ± standard deviation of quadruplicate wells (*** p < 
0.0001 versus control, ANOVA followed by Bonferroni multiple comparisons test). The cartoon 
representation of each glycan (in SNFG nomenclature) is shown below the corresponding panel, along 
with a key for the monosaccharides. B) A panel of cancer cell lines were stained with FG28/11 mAb 
(5µg/ml) and analysed by flow cytometry. The anti-HLA-A,B,C mAb W6/32 (1µg/ml) and no primary 
mAb were included as positive and negative controls, respectively. Results were expressed as 
Geometric mean (Gm) with % CV. C) Binding of FG28/11 (1µg/ml) antibody to (i) ovarian and (ii) 
































Figure 2. Production and crystallization of ch28/11 Fab. A) Coomassie stained SDS-PAGE gel. Lanes 
correspond to: 1, protein marker; 2 and 6, ch28/11 IgG; 3, and 7, antibody digest; 4 and 8, purified Fab; 
5 and 9, undigested IgG and Fc fraction. Samples in lanes 6-9 were reduced using β-mercaptoethanol. 
B) Size distribution analysis of DLS data for ch28/11 IgG and ch28/11 Fab. C) Co-crystals of ch28/11 
Fab in complex with SSEA-4 (P41212 crystal form; scale bar, 200 microns). D) Composite omit 2Fo – 
Fc map (displayed at 1.5σ level) for the 1.5 Å resolution ch28/11 Fab:SSEA-4 complex. Residues from 
Fab are depicted as lines with L chain in blue and H chain in purple, with the ligand displayed as sticks 


























Table 1. Data collection and crystallographic refinement statistics. Values in parentheses refer to the 
highest resolution shell for each data set. Collection statistics were compiled from XDS, and refinement 
statistics from Phenix and CCP4, using MolProbity for Ramachandran statistics.  
 




Fab:SSEA-4 ch28/11 Fab 
Data collection     
      Space group P41212 P21 P62 P21 
      Unit cell dimensions (Å) a = 67.8, b = 67.8, c = 234.0 
a = 37.5, b = 
69.1, c = 97.7 
a = 170.1, b = 
170.1, c = 95.4 
a = 75.2, b = 
69.6, c = 93.9 
      Unit cell angles (°) α = 90.0, β = 90.0, γ = 90.0 
α = 90.0, β = 
94.5, γ = 90.0 
α = 90.0, β = 
90.0, γ = 120.0 
α = 90.0, β = 
98.3, γ = 90.0 
      Resolution range (Å) 50 – 1.5 (1.6 – 1.5) 
50 – 1.9 (2.0 – 
1.9) 
50 – 2.7 (2.8 – 
2.7) 
50 – 2.5 (2.6 – 
2.5) 
      Number of unique reflections 84916 (13419) 39580 (6187) 41405 (6561) 33478 (5126) 
      Data completeness (%) 99.9 (99.2) 99.3 (96.8) 99.7 (98.6) 98.1 (93.9) 
      Average multiplicity  13.3 (13.4) 3.4 (3.4) 5.3 (5.2) 3.4 (3.5) 
      R-factor 0.10 (0.46) 0.06 (0.48) 0.13 (0.69) 0.06 (0.41) 
      Rmeas 0.10 (0.48) 0.07 (0.57) 0.14 (0.77) 0.07 (0.48) 
      Mean I/σ (I) 15.8 (4.2) 10.1 (1.9) 10.6 (2.3) 14.4 (2.6) 
Crystallographic refinement     
      Rwork 0.172 0.176 0.169 0.164 
      Rfree 0.197 0.230 0.246 0.239 
      Average B-factor from Wilson 
plot (Å2) 19.5 34.4 52.7 52.1 
rmsd from ideal values     
      Bond lengths (Å) 0.018 0.018 0.012 0.014 
      Bond angles (O)  1.9 1.9 1.7 1.7 
Ramachandran plot values (%)     
      Favored regions 98.6 97.9 96.2 96.8 
      Allowed regions 1.2 2.1 3.4 3.0 
      Outliers  0.2 0 0.4 0.2 
Average B-factor (Å2)     
      Protein atoms 23.1 41.6 54.9 58.8 
      Carbohydrate atoms 26.4 38.3 61.2 - 















Figure 3. Overview of the crystal structures of ch28/11 Fab bound to SSEA-4. A) Overlay of the five 
complexes, with the Fab shown as ribbons with the L chain in blue and the H chain in magenta. B) 
Overlay of the five ch28/11 Fab:SSEA-4 complexes looking down into the binding site (end-on view). 
For clarity only the VL and VH domains of each Fab are shown. CDRs are shown in pale blue (L chain) 
and pale pink (H chain). SSEA-4 glycan ligands are shown with carbon atoms in yellow (P41212 crystal 
form), orange (P21 crystal form) and green (P62 crystal form). C) End-on solvent-accessible view of 
the 1.5 Å resolution ch28/11 Fab:SSEA-4 complex (VL, blue; VH, magenta; L chain CDRs, pale blue; 










Figure 4. Overlay of SSEA-4 from the five ch28/11 Fab crystal structures. A) Top view. B) Side view 
(rotated 90 degrees). The ligands are depicted as sticks colored by sugar type, with glucose (BGC) in 
yellow, galactose (GAL and GLA) in red, N-acetyl-galactosamine (NGA) in blue and sialic acid (SIA) 
in green.  C) Sugar residue conformations of SSEA-4 bound to ch28/11 in the five crystal structures, 
















Figure 5. Details of the interactions between ch28/11 Fab and SSEA-4 from the highest resolution 
crystal structure. A) Side view and B) Top view (rotated 90 degrees). Residues from Fab are depicted 
as thin sticks: L chain CDR residues, pale blue; H chain CDR residues, pale pink; L chain framework 
residue, blue. Glycan ligands are depicted as thick sticks colored by atom type (C, yellow; O, red; N, 
blue). From left to right, glycans are BGC6, GAL5, GLA4, NGA3, GAL2, SIA1 (see Fig 4). Amino 
acids are labeled (1 letter code) and sequential numbering is shown (see Fig. S4 for IMGT numbering 
scheme). Hydrogen bonds (dashed black lines) are displayed between the SSEA-4 hexasaccharide and 
Fab or water molecules (light blue spheres). Labels a, b and c (shown in blue) correspond to the O2 

















Figure 6. Surface representation of the ch28/11 Fab:SSEA-4 complex. A) Side view. B) Top view 
(rotated 90 degrees). Solvent-accessible surfaces for the ch28/11 Fab (white) and SSEA-4 (yellow, 
transparent) are shown, with water molecules displayed as light blue spheres. The SSEA-4 ligand 










Figure 7. The unliganded ch28/11 Fab structure compared to the 1.5 Å resolution ch28/11 Fab bound 
to SSEA-4. CDR residues from ch28/11 Fab:SSEA-4 (light grey sticks) with ch28/11 Fab 1 (yellow 
sticks) and ch28/11 Fab 2 (light blue sticks). Differences between free and bound Fabs are more 



























Figure 8. MD simulations of ch28/11 Fab complexes with SSEA-3 and SSEA-4. RMSF plots of glycan 
atoms with residues indicated by dashed lines for A) SSEA-3 and B) SSEA-4. MD simulations (500 
ns) were performed in triplicate, averaged over time, and are represented as green, orange and blue 
traces. Phi (ϕ) vs. psi (ψ) density plots of each glycosidic linkage of C) SSEA-3 and D) SSEA-4. Angles 
were averaged over time for the 3 simulations. E) The 2 main conformations of SSEA-3, represented 
as sticks with carbon atoms in grey and dark blue.  
 
 
